TheStreet downgrades Boston Scientific — 3 insights

TheStreet downgraded Boston Scientific from a "B" to a "C" rating in a recent research report.

Here's what you should know.

1. TheStreet joins several other analysts in downgrading the industry giant.

2. Yet, despite the recent downgrades, Boston Scientific still has 13 "buy" ratings, six "hold" ratings and a single "sell" rating.

3. Analysts attached an average price target of $31.06 per share to the stock.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast